Increased G6PDH activity is closely associated with all cancers, including kidney cancer (Spencer and Stanton, 2017), and represents an important prognosticator for poor outcome in RCC, as well as a potential therapeutic target for developing effective RCC treatment strategies (Zhang et al., 2017b). Here, H6PD is linked to kidney cancer.